Legal & General Group PLC Ionis Pharmaceuticals Inc Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Legal & General Group PLC holds 161,643 shares of IONS stock, worth $6.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

161,643

Previous 149,488 8.13%

Holding current value

$6.6 Million

Previous $6.48 Million 18.87%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$36.45 - $47.7 $443,049 - $579,793	12,155 Added 8.13%	161,643 $7.7 Million
Q1 2024 Jul 01, 2024	BUY	$42.03 - $53.55 $491,330 - $625,999	11,690 Added 8.48%	149,488 $6.48 Million
Q1 2024 May 14, 2024	SELL	$42.03 - $53.55 $737,626 - $939,802	-17,550 Reduced 11.3%	137,798 $5.97 Million
Q4 2023 Feb 15, 2024	SELL	$43.39 - $51.63 $420,318 - $500,139	-9,687 Reduced 5.87%	155,348 $7.86 Million
Q3 2023 Nov 14, 2023	BUY	$38.5 - $47.13 $1.22 Million - $1.49 Million	31,692 Added 23.77%	165,035 $7.49 Million
Q2 2023 Aug 14, 2023	SELL	$34.73 - $43.33 $256,133 - $319,558	-7,375 Reduced 5.24%	133,343 $5.47 Million
Q1 2023 May 15, 2023	BUY	$33.58 - $41.2 $457,695 - $561,556	13,630 Added 10.72%	140,718 $5.03 Million
Q4 2022 Feb 14, 2023	SELL	$37.12 - $46.52 $50,668 - $63,499	-1,365 Reduced 1.06%	127,088 $4.8 Million
Q3 2022 Nov 14, 2022	SELL	$36.54 - $48.66 $1.3 Million - $1.73 Million	-35,501 Reduced 21.65%	128,453 $5.68 Million
Q2 2022 Aug 22, 2022	BUY	$31.71 - $43.0 $51,877 - $70,348	1,636 Added 1.01%	163,954 $6.07 Million
Q1 2022 May 16, 2022	BUY	$29.88 - $37.04 $118,743 - $147,196	3,974 Added 2.51%	162,318 $6.01 Million
Q4 2021 Feb 14, 2022	SELL	$25.61 - $35.1 $232,461 - $318,602	-9,077 Reduced 5.42%	158,344 $4.82 Million
Q3 2021 Nov 15, 2021	BUY	$33.54 - $40.55 $1.39 Million - $1.68 Million	41,538 Added 33.0%	167,421 $5.62 Million
Q2 2021 Aug 12, 2021	SELL	$34.54 - $47.25 $10.2 Million - $13.9 Million	-294,494 Reduced 70.05%	125,883 $5.02 Million
Q1 2021 May 17, 2021	SELL	$42.51 - $63.78 $1.93 Million - $2.89 Million	-45,321 Reduced 9.73%	420,377 $18.9 Million
Q4 2020 Feb 12, 2021	BUY	$45.3 - $60.27 $1.41 Million - $1.88 Million	31,193 Added 7.18%	465,698 $26.3 Million
Q3 2020 Nov 13, 2020	SELL	$47.45 - $62.95 $874,883 - $1.16 Million	-18,438 Reduced 4.07%	434,505 $20.6 Million
Q2 2020 Aug 14, 2020	BUY	$46.85 - $61.05 $838,849 - $1.09 Million	17,905 Added 4.12%	452,943 $26.7 Million
Q1 2020 May 14, 2020	BUY	$41.6 - $63.4 $1.18 Million - $1.8 Million	28,404 Added 6.99%	435,038 $20.6 Million
Q4 2019 Feb 13, 2020	BUY	$53.85 - $65.27 $882,386 - $1.07 Million	16,386 Added 4.2%	406,634 $24.6 Million
Q3 2019 Nov 13, 2019	BUY	$59.06 - $72.15 $2.04 Million - $2.49 Million	34,465 Added 9.69%	390,248 $23.4 Million
Q2 2019 Aug 14, 2019	BUY	$62.09 - $86.14 $17.6 Million - $24.4 Million	283,306 Added 390.89%	355,783 $22.9 Million
Q1 2019 May 15, 2019	BUY	$52.92 - $81.17 $100,600 - $154,304	1,901 Added 2.69%	72,477 $5.88 Million
Q4 2018 Feb 15, 2019	BUY	$43.37 - $59.54 $375,280 - $515,199	8,653 Added 13.97%	70,576 $3.82 Million
Q3 2018 Nov 20, 2018	BUY	$42.88 - $53.7 $130,440 - $163,355	3,042 Added 5.17%	61,923 $3.19 Million
Q2 2018 Aug 10, 2018	SELL	$40.53 - $50.7 $387,912 - $485,249	-9,571 Reduced 13.98%	58,881 $2.45 Million
Q1 2018 May 17, 2018	BUY	$44.08 - $55.05 $84,854 - $105,971	1,925 Added 2.89%	68,452 $3.02 Million
Q4 2017 Feb 13, 2018	BUY	$50.3 - $64.39 $3.35 Million - $4.28 Million	66,527	66,527 $3.35 Million

Others Institutions Holding IONS

# of Institutions

394

Shares Held

125M

Call Options Held

2.25M

Put Options Held

510K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.8B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Ionis Pharmaceuticals Inc Transaction History